索拉非尼联合化疗用于治疗胃癌细胞株的实验研究  

Study of Sorafenib combined with chemotherapy on advanced gastric cancer cell line

作　　者：陈建勇[1] 刘晖[1] 王爱瑶[1] 

机构地区：[1]江西省人民医院消化科,南昌330006

出　　处：《江西医药》2013年第2期95-97,共3页Jiangxi Medical Journal

基　　金：江西省卫生厅科技计划(20091007-1)

摘　　要：目的观察索拉非尼治疗胃癌细胞株的作用机制。方法将胃癌MGC803细胞株扩大培养后,分为4组:对照组,索拉非尼单药组,化疗组,索拉非尼联合化疗同时给药组。各组经处理后观察细胞生长曲线,采用流式细胞仪检测细胞凋亡,MTT检测细胞增殖率,RT-PCR和Western blot法检测EGFR、VEGF的表达。结果索拉非尼联合化疗组细胞增殖率明显下降,细胞明显凋亡。结论索拉非尼联合化疗对胃癌有较好的治疗作用。Objective To observe Sorafenib for treatment effect advanced garstric cancer cell line.Methods The gastric cancer cell line MGC803 was expanded culture,cell groups： control group,Sorafenib single medicine group,chemotherapy group,Sorafenib combination chemotherapy at the same time giving medicine group.After being treatedal groups was observed for cell growth curve,flow cell meter method measuring cell apoptosis,MTT detection for the cell vitality,RT-PCR and Western blot method measuring the expression of EGFR,VEGF was measued.Results of Sorafenib combined chemotherapy group The ceuvitality declined obviously,and cell apoptosis was significantly.Conclusion Sorafenib combination chemotherapy for gastric cancer has better therapeutic action.

关 键 词：索拉非尼 化疗 胃癌细胞株 细胞凋亡 

分 类 号：R735[医药卫生—肿瘤]